Search Results
You are looking at 1 - 3 of 3 items for
- Author: Carlos Martinez x
- Refine by access: All content x
Search for other papers by Olga Lakiza in
Google Scholar
PubMed
Search for other papers by Julian Lutze in
Google Scholar
PubMed
Search for other papers by Alyx Vogle in
Google Scholar
PubMed
Search for other papers by Jelani Williams in
Google Scholar
PubMed
Search for other papers by Abde Abukdheir in
Google Scholar
PubMed
Search for other papers by Paul Miller in
Google Scholar
PubMed
Search for other papers by Chih-Yi ‘Andy’ Liao in
Google Scholar
PubMed
Search for other papers by Sean P Pitroda in
Google Scholar
PubMed
Search for other papers by Carlos Martinez in
Google Scholar
PubMed
Search for other papers by Andrea Olivas in
Google Scholar
PubMed
Search for other papers by Namrata Setia in
Google Scholar
PubMed
Department of Molecular Genetics and Cell Biology, University of Chicago, Chicago, Illinois, USA
Search for other papers by Stephen J Kron in
Google Scholar
PubMed
Ludwig Center for Metastasis Research, University of Chicago, Chicago, Illinois, USA
Search for other papers by Ralph R Weichselbaum in
Google Scholar
PubMed
Search for other papers by Xavier M Keutgen in
Google Scholar
PubMed
Somatic MEN1 mutations occur in up to 50% of pancreatic neuroendocrine tumors (PanNETs). Clinical studies have shown that radiation therapy (IR) is effective in a subset of PanNETs, but it remains unclear why some patients respond better to IR than others. Herein, we study whether MEN1 loss of function increases radiosensitivity of PanNETs and determine its effect on DNA double-strand break (DSB) repair. After creating a MEN1 knockout PanNET cell line, we confirmed reduced DSB repair capacity in MEN1-deficient cells and linked these findings to a defect in homologous recombination, as well as reduced BRCA2 expression levels. Consistent with this model, we found that MEN1 mutant cells displayed increased sensitivity to the highly trapping poly (ADP-ribose) polymerase (PARP) 1 inhibitor talazoparib in vitro. Our results suggest that combining IR with PARP inhibition may be beneficial in patients with PanNETs and MEN1 loss of function.
Search for other papers by Roberto Olmos in
Google Scholar
PubMed
Search for other papers by José Miguel Domínguez in
Google Scholar
PubMed
Search for other papers by Sergio Vargas-Salas in
Google Scholar
PubMed
Search for other papers by Lorena Mosso in
Google Scholar
PubMed
Search for other papers by Carlos E Fardella in
Google Scholar
PubMed
Search for other papers by Gilberto González in
Google Scholar
PubMed
Search for other papers by René Baudrand in
Google Scholar
PubMed
Search for other papers by Francisco Guarda in
Google Scholar
PubMed
Search for other papers by Felipe Valenzuela in
Google Scholar
PubMed
Search for other papers by Eugenio Arteaga in
Google Scholar
PubMed
Search for other papers by Pablo Forenzano in
Google Scholar
PubMed
Search for other papers by Flavia Nilo in
Google Scholar
PubMed
Search for other papers by Nicole Lustig in
Google Scholar
PubMed
Search for other papers by Alejandra Martínez in
Google Scholar
PubMed
Search for other papers by José M López in
Google Scholar
PubMed
Search for other papers by Francisco Cruz in
Google Scholar
PubMed
Search for other papers by Soledad Loyola in
Google Scholar
PubMed
Search for other papers by Augusto Leon in
Google Scholar
PubMed
Search for other papers by Nicolás Droppelmann in
Google Scholar
PubMed
Search for other papers by Pablo Montero in
Google Scholar
PubMed
Search for other papers by Francisco Domínguez in
Google Scholar
PubMed
Search for other papers by Mauricio Camus in
Google Scholar
PubMed
Search for other papers by Antonieta Solar in
Google Scholar
PubMed
Search for other papers by Pablo Zoroquiain in
Google Scholar
PubMed
Search for other papers by Juan Carlos Roa in
Google Scholar
PubMed
Search for other papers by Estefanía Muñoz in
Google Scholar
PubMed
Search for other papers by Elsa Bruce in
Google Scholar
PubMed
Search for other papers by Rossio Gajardo in
Google Scholar
PubMed
Search for other papers by Giovanna Miranda in
Google Scholar
PubMed
Search for other papers by Francisco Riquelme in
Google Scholar
PubMed
Search for other papers by Natalia Mena in
Google Scholar
PubMed
Search for other papers by Hernán E González in
Google Scholar
PubMed
Molecular testing contributes to improving the diagnosis of indeterminate thyroid nodules (ITNs). ThyroidPrint® is a ten-gene classifier aimed to rule out malignancy in ITN. Post-validation studies are necessary to determine the real-world clinical benefit of ThyroidPrint® in patients with ITN. A single-center, prospective, noninterventional clinical utility study was performed, analyzing the impact of ThyroidPrint® in the physicians’ clinical decisions for ITN. Demographics, nodule characteristics, benign call rates (BCRs), and surgical outcomes were measured. Histopathological data were collected from surgical biopsies of resected nodules. Of 1272 fine-needle aspirations, 109 (8.6%) were Bethesda III and 135 (10.6%) were Bethesda IV. Molecular testing was performed in 155 of 244 ITN (63.5%), of which 104 were classified as benign (BCR of 67.1%). After a median follow-up of 15 months, 103 of 104 (99.0%) patients with a benign ThyroidPrint® remained under surveillance and one patient underwent surgery which was a follicular adenoma. Surgery was performed in all 51 patients with a suspicious for malignancy as per ThyroidPrint® result and in 56 patients who did not undergo testing, with a rate of malignancy of 70.6% and 32.1%, respectively. A higher BCR was observed in follicular lesion of undetermined significance (87%) compared to atypia of undetermined significance (58%) (P < 0.05). False-positive cases included four benign follicular nodules and six follicular and four oncocytic adenomas. Our results show that, physicians chose active surveillance instead of diagnostic surgery in all patients with a benign ThyroidPrint® result, reducing the need for diagnostic surgery in 67% of patients with preoperative diagnosis of ITN.
Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain
Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain
Biomedical Research Networking Center in Rare Diseases (CIBERER), Institute of Health Carlos III (ISCIII), Madrid, Spain
Search for other papers by Manel Puig-Domingo in
Google Scholar
PubMed
Search for other papers by Joan Gil in
Google Scholar
PubMed
Department of Endocrinology, Hospital de la Princesa, Universidad Autónoma de Madrid, Instituto Princesa, Madrid, Spain
Search for other papers by Miguel Sampedro-Nuñez in
Google Scholar
PubMed
Search for other papers by Mireia Jordà in
Google Scholar
PubMed
Search for other papers by Susan M Webb in
Google Scholar
PubMed
Search for other papers by Guillermo Serra in
Google Scholar
PubMed
Search for other papers by Laura Pons in
Google Scholar
PubMed
Search for other papers by Isabel Salinas in
Google Scholar
PubMed
Search for other papers by Alberto Blanco in
Google Scholar
PubMed
Search for other papers by Montserrat Marques-Pamies in
Google Scholar
PubMed
Search for other papers by Elena Valassi in
Google Scholar
PubMed
Hospital General Universitario de Alicante-Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
Department of Clinical Medicine, Miguel Hernández University, Elche, Spain
Search for other papers by Antonio Picó in
Google Scholar
PubMed
Hospital General Universitario de Alicante-Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
Search for other papers by Araceli García-Martínez in
Google Scholar
PubMed
Search for other papers by Cristina Carrato in
Google Scholar
PubMed
Department of Cellular and Molecular Physiology, Penn State College of Medicine, Hershey, Pennsylvania, USA
Search for other papers by Raquel Buj in
Google Scholar
PubMed
Search for other papers by Carlos del Pozo in
Google Scholar
PubMed
Search for other papers by Gabriel Obiols in
Google Scholar
PubMed
Search for other papers by Carles Villabona in
Google Scholar
PubMed
Search for other papers by Rosa Cámara in
Google Scholar
PubMed
Search for other papers by Carmen Fajardo-Montañana in
Google Scholar
PubMed
Search for other papers by Clara V Alvarez in
Google Scholar
PubMed
Search for other papers by Ignacio Bernabéu in
Google Scholar
PubMed
Department of Endocrinology, Hospital de la Princesa, Universidad Autónoma de Madrid, Instituto Princesa, Madrid, Spain
Search for other papers by Mónica Marazuela in
Google Scholar
PubMed
Pharmacologic treatment of acromegaly is currently based upon assay-error strategy, the first-generation somatostatin receptor ligands (SRL) being the first-line treatment. However, about 50% of patients do not respond adequately to SRL. Our objective was to evaluate the potential usefulness of different molecular markers as predictors of response to SRL. We used somatotropinoma tissue obtained after surgery from a national cohort of 100 acromegalic patients. Seventy-one patients were treated with SRL during at least 6 months under maximal therapeutic doses according to IGF1 values. We analyzed the expression of SSTR2, SSTR5, AIP, CDH1 (E-cadherin), MKI67 (Ki-67), KLK10, DRD2, ARRB1, GHRL, In1-Ghrelin, PLAGL1 and PEBP1 (RKIP) by RT-qPCR and mutations in GNAS gene by Sanger sequencing. The response to SRL was categorized as complete response (CR), partial (PR) or non-response (NR) if IGF1 was normal, between >2<3 SDS or >3 SDS IGF1 at 6 months of follow-up, respectively. From the 71 patients treated, there were 27 CR (38%), 18 PR (25%) and 26 NR (37%). SSTR2, Ki-67 and E-cadherin were associated with SRL response (P < 0.03, P < 0.01 and P < 0.003, respectively). E-cadherin was the best discriminator for response prediction (AUC = 0.74, P < 0.02, PPV of 83.7%, NPV of 72.6%), which was validated at protein level. SSTR5 expression was higher in patients pre-treated with SRL before surgery. We conclude that somatotropinomas showed heterogeneity in the expression of genes associated with SRL response. E-cadherin was the best molecular predictor of response to SRL. Thus, the inclusion of E-cadherin in subsequent treatment-decision after surgical failure may be useful in acromegaly.
